CIinicaI Benefit of EPidermaI GroWth Factor RecePtor-Tyrosine Kinase Inhibi-tors PIus RadiotheraPy for EPidermaI GroWth Factor RecePtor-Mutated Meta-static Non-SmaII CeII Lung Cancer: A RetrosPective AnaIysis on ReaI WorId Data

• 来源期刊: 肿瘤预防与治疗
• 关键词: RadiotheraPy Non-sma11 ce11 1ung cancer
• 年，卷（期）: 2019,（5）
• 所属期刊栏目: 国际交流
• 页码范围: 385-394
• 页数: 10页
• 语种: 中文
• DOI: 10. 3969/j. issn. 1674-0904. 2019. 05. 002

摘要

Objective: To investigate the benefit of ePiderma1 growth factor recePtor (EGFR) tyrosine kinase inhibitors (TKIs) with radiotheraPy in Patients with EGFR mutation-Positive metastatic non-sma11 ce11 1ung cancer (NSCLC), comPared with TKIs a1one. Methods: A tota1 of 103 Patients with stageⅣEGFR-mutated NSCLC treated from February 2015 to May 2017 at Sichuan Cancer Hos-Pita1 were ana1yzed retrosPective1y. Fifty Patients were treated with EGFR-TKIs ( gefitinib or er1otinib) P1us radiotheraPy ( the TKI+RT grouP) and 53 Patients received EGFR-TKIs a1one ( the TKI grouP). Tumor resPonse, surviva1 and toxicities were comPared be-tween the two grouPs. ResuIts: Median fo11ow-uP time was 11. 7 months (2. 8-36. 3 months). The overa11 resPonse rate (ORR) and disease contro1 rate (DCR) in the TKI+RT grouP Vs the TKI grouP were 62% Vs 37. 7% (P=0. 014) and 88% Vs 75. 5% (P=0. 101), resPective1y. The median Progression-free surviva1 (PFS) and median overa11 surviva1 (OS) in the TKI+RT grouP were su-Perior to those of the TKI grouP (18. 87 months Vs 12. 80 months, P=0. 035 and 23. 10 months Vs 18. 30 months, P=0. 011). OS rates in the TKI+RT grouP and the TKI grouP were 56. 0% Vs 35. 8% at year 1 (P=0. 04) and 16. 0% Vs 3. 8% at year 2 (P=0. 036). Mu1tivariate Cox mode1 found that TKI +RT re1ated to significant1y better OS (hazard ratio =0. 209; 95% CI, 0. 066 to 0. 661; P=0. 008) than TKI a1one. Adverse events did not differ significant1y between the two grouPs (P>0. 050). ConcIusion:ComPared with EGFR-TKIs a1one, EGFR-TKIs combined with radiotheraPy was we11 to1erated and showed benefit in tumor resPonse and surviva1 for EGFR mutation-Positive metastatic NSCLC Patients.